Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Profit After Tax: 2017-2025

Historic Profit After Tax for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$39.3 million.

  • Protagonist Therapeutics' Profit After Tax fell 18.46% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 73.13%. This contributed to the annual value of $275.2 million for FY2024, which is 448.54% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Profit After Tax of -$39.3 million as of Q3 2025, which was down 13.14% from -$34.8 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Profit After Tax peaked at $207.3 million during Q1 2024, and registered a low of -$41.0 million during Q2 2022.
  • For the 3-year period, Protagonist Therapeutics' Profit After Tax averaged around $10.0 million, with its median value being -$33.2 million (2024).
  • Per our database at Business Quant, Protagonist Therapeutics' Profit After Tax tumbled by 335.45% in 2021 and then skyrocketed by 714.80% in 2024.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' Profit After Tax stood at -$36.9 million in 2021, then climbed by 7.35% to -$34.2 million in 2022, then surged by 179.94% to $27.3 million in 2023, then skyrocketed by 381.70% to $131.7 million in 2024, then decreased by 18.46% to -$39.3 million in 2025.
  • Its last three reported values are -$39.3 million in Q3 2025, -$34.8 million for Q2 2025, and -$11.7 million during Q1 2025.